logo
NasdaqGM:VRCA logo

Verrica Pharmaceuticals Community

NasdaqGM:VRCA Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

VRCA logo
Verrica Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts

Turnaround Plan Will Commercialize YCANTH And Advance Pipeline

Key Takeaways Cost reductions and focus on YCANTH commercialization could improve future revenues and net margins, aiding the turnaround plan. New market opportunities and pipeline progress with VP-315 and YCANTH could significantly boost future revenue if successful.
View narrative
US$3.33
FV
81.6% undervalued intrinsic discount
92.45%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
5 days ago author updated this narrative